PDF Report (2.2Mb)
View other formats
Cervical screening in Australia 2014–2015 presents the latest national statistics monitoring the National Cervical Screening Program, which aims to reduce incidence, morbidity and mortality from cervical cancer. Just over half (56%) of women in the target age group of 20–69 took part in the program, with more than 3.8 million women screening in 2014 and 2015. Cervical cancer incidence for women of all ages remains at an historical low of 7 new cases per 100,000 women, and deaths are also low, historically and by international standards, at 2 deaths per 100,000 women.
In 2013, 692 women aged 20–69 were diagnosed with cervical cancer
In 2014, 149 women aged 20–69 died from cervical cancer
In 2014–2015, more than 3.8 million women participated in cervical screening. This was 56% of women aged 20–69
In 2014, of the women sent a 27-month reminder letter by a cervical screening register, 32% rescreened within 3 months
The National Cervical Screening Program (NCSP) aims to reduce cervical cancer cases, as well as illness and death from cervical cancer in Australia, through an organised approach to cervical screening aimed at detecting and treating high-grade abnormalities before possible progression to cervical cancer. This report is the latest in the Cervical screening in Australia series, which is published annually to provide regular monitoring of the NCSP.
The following data are for women aged 20–69.
In 2013, 692 women aged 20–69 were diagnosed with cervical cancer, and 149 women died from the disease in 2014. This is equivalent to 9 new cases of cervical cancer diagnosed per 100,000 women and 2 deaths per 100,000 women. These rates are similar to previous years. Both incidence and mortality halved between the introduction of the NCSP in 1991 and the year 2002, and have since remained at 9 to 10 new cases, and 2 deaths, per 100,000 women.
In 2014–2015, more than 3.8 million women participated in cervical screening. This was 56% of women aged 20–69. The age-standardised participation of 57% is similar to previous years, with age-standardised participation in 2012–2013 and 2013–2014 at 58%.
Participation varied across remoteness areas, ranging from 52% for Very remote areas to 58% for Inner regional areas. There was a clear association between participation and socioeconomic group, with participation rising from 51% for women in the lowest socioeconomic group to 63% for those in the highest socioeconomic group.
Only 11% of women with a negative screen in 2014 rescreened earlier than the recommended 2 years, continuing a downward trend. Of women who were sent a 27-month reminder letter by a cervical screening register, 32% rescreened within 3 months—similar to previous years.
In 2015, for every 1,000 women screened, 8 women had a high-grade abnormality detected by histology, providing an opportunity for treatment before possible progression to cancer. This is similar to previous years, for which the age-standardised rate was between 8 and 9.
There has been a decline in the rate of detection of high-grade abnormalities for women under 25, which has shifted the historical peak age of high-grade abnormalities from 20–24 to 25–29. This is likely to be due to girls being vaccinated against HPV under the National HPV Vaccination Program. It is expected that, as this vaccinated cohort continues to age, older age groups will experience a similar decline in the detection rate of high-grade abnormalities.
National participation rates for Aboriginal and Torres Strait Islander women are not available, due to Indigenous status information not being collected on pathology forms in all jurisdictions, but there is strong evidence that this population group is under-screened. Incidence of cervical cancer in Aboriginal and Torres Strait Islander women is more than twice that of non-Indigenous women, and mortality is 4 times the non-Indigenous rate.
We'd love to know any feedback that you have about the AIHW website, its contents or reports.